Zhejiang Hisoar Pharmaceutical Hits Day Low Amid Price Pressure at CNY 6.35

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a notable decline in its stock performance on March 23, 2026, with a decrease of 4.46%. The stock reached an intraday low of CNY 6.35, reflecting ongoing challenges within the company. Over the past week, the stock has fallen by 11.43%, and its monthly performance shows a decline of 14.04%. In terms of annual performance, Zhejiang Hisoar has managed a 27.08% increase over the past year, which contrasts sharply with its longer-term performance metrics. The company has faced significant hurdles, including a negative annual growth rate in net sales of 5.79% and a staggering operating profit decline of 179.56% over the last five years. Financial indicators reveal a low return on capital employed of 2.16%, suggesting limited profitability relative to total capital. Additionally, the company reported a net profit of CNY -83.69 million, marking a 162.86% decline. With a market capitalization of CNY 11,906 million, Zhejiang Hisoar continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.